ATE530530T1 - Diaminopyrimidincarbonsäureamidderivat - Google Patents

Diaminopyrimidincarbonsäureamidderivat

Info

Publication number
ATE530530T1
ATE530530T1 AT03761820T AT03761820T ATE530530T1 AT E530530 T1 ATE530530 T1 AT E530530T1 AT 03761820 T AT03761820 T AT 03761820T AT 03761820 T AT03761820 T AT 03761820T AT E530530 T1 ATE530530 T1 AT E530530T1
Authority
AT
Austria
Prior art keywords
diaminopyrimidine
acid amide
carbonic acid
amide derivative
substituted
Prior art date
Application number
AT03761820T
Other languages
English (en)
Inventor
S Nagashima
H Nagata
M Iwata
M Yokota
H Moritomo
E Nakai
S Kuromitsu
K Ohga
M Takeuchi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE530530T1 publication Critical patent/ATE530530T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT03761820T 2002-06-28 2003-06-26 Diaminopyrimidincarbonsäureamidderivat ATE530530T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002190959 2002-06-28
PCT/JP2003/008129 WO2004002964A1 (ja) 2002-06-28 2003-06-26 ジアミノピリミジンカルボキサミド誘導体

Publications (1)

Publication Number Publication Date
ATE530530T1 true ATE530530T1 (de) 2011-11-15

Family

ID=29996904

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03761820T ATE530530T1 (de) 2002-06-28 2003-06-26 Diaminopyrimidincarbonsäureamidderivat

Country Status (10)

Country Link
US (3) US7449456B2 (de)
EP (1) EP1518855B1 (de)
JP (2) JP4529685B2 (de)
CN (1) CN1665789A (de)
AT (1) ATE530530T1 (de)
AU (1) AU2003244098A1 (de)
CA (1) CA2490888C (de)
ES (1) ES2373226T3 (de)
MX (1) MXPA04012855A (de)
WO (1) WO2004002964A1 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
DE10223662A1 (de) 2002-05-28 2003-12-11 Mitsubishi Polyester Film Gmbh Transparente Polyesterfolie mit verbesserter Wasserdampfbarriere, Verfahren zu ihrer Herstellung und ihre Verwendung
JP4529685B2 (ja) * 2002-06-28 2010-08-25 アステラス製薬株式会社 ジアミノピリミジンカルボキサミド誘導体
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
EP1576134B1 (de) * 2002-12-09 2013-03-06 Judith Kelleher-Andersson Verfahren zur entdeckung neurogener wirkstoffe
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
BR122019017579B8 (pt) 2003-08-15 2021-07-27 Novartis Ag 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CN101115761B (zh) 2005-01-19 2012-07-18 里格尔药品股份有限公司 2,4-嘧啶二胺化合物的前药及其应用
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ, インコーポレイテッド Jakキナーゼインヒビターおよびそれらの使用
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
AU2006254840B2 (en) 2005-06-08 2012-08-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EA015890B1 (ru) * 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
US7671058B2 (en) * 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
WO2008009458A1 (en) * 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
EP2222647B1 (de) 2006-10-23 2015-08-05 Cephalon, Inc. Kondensierte bicyclische derivate von 2,4-diaminopyrimidin als alk- und c-met-inhibitoren
KR101364277B1 (ko) 2006-12-08 2014-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
AU2008275918B2 (en) 2007-07-17 2014-01-30 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
WO2009119528A1 (ja) * 2008-03-24 2009-10-01 武田薬品工業株式会社 複素環化合物
CA2728893C (en) * 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
EP2321283B1 (de) * 2008-04-16 2016-07-13 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamide als syk oder jak kinase inhibitoren
SI2321283T1 (sl) * 2008-04-16 2017-01-31 Portola Pharmaceuticals, Inc. 2,6-diamino-pirimidin-5-il-karboksamidi kot inhibitorji SYK ali JAK kinaze
MX2010011463A (es) 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
DK2268635T3 (en) 2008-04-21 2015-09-14 Taigen Biotechnology Co Ltd Heterocyclic Compounds
AU2009320683B2 (en) * 2008-11-28 2012-07-19 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
FR2941698B1 (fr) 2009-01-30 2012-07-27 France Etat Procede d'identification de microorganisme, sans a priori et kit d'identification
AR076550A1 (es) * 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
CA2760061C (en) 2009-05-08 2017-02-28 Astellas Pharma Inc. Diamino heterocyclic carboxamide compound
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
WO2011065800A2 (ko) * 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ, インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
AU2012245387C1 (en) 2011-04-22 2016-05-05 Signal Pharmaceuticals, Llc Substituted Diaminocarboxamide and Diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
AU2016244228B2 (en) * 2011-04-22 2019-02-21 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
AU2015201030B2 (en) * 2011-04-22 2016-09-29 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
WO2013054351A1 (en) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
SG11201402570QA (en) 2011-11-23 2014-06-27 Portola Pharm Inc Pyrazine kinase inhibitors
CA2856306A1 (en) * 2011-11-23 2013-05-30 Portola Pharmaceuticals, Inc. Selective kinase inhibitors
US9242976B2 (en) 2012-01-13 2016-01-26 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2013106612A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
EP2802577B1 (de) 2012-01-13 2017-03-01 Bristol-Myers Squibb Company Triazolylsubstituierte pyridylverbindungen als kinaseinhibitoren
RU2014145121A (ru) * 2012-05-22 2016-07-10 Зэ Юниверсити Оф Норд Каролина Эт Чапел Хилл Пиримидиновые соединения для лечения злокачественной опухоли
EP2711365A1 (de) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidine verwendbar für die Behandlung von Krebs
EP2711364A1 (de) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl oder benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidine verwendbar für die Behandlung von Krebs
WO2014060371A1 (en) 2012-10-19 2014-04-24 F. Hoffmann-La Roche Ag Inhibitors of syk
SG11201503395TA (en) * 2012-11-08 2015-05-28 Bristol Myers Squibb Co ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα
PE20150953A1 (es) 2012-11-08 2015-06-20 Bristol Myers Squibb Co Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
ES2616812T3 (es) 2012-11-08 2017-06-14 Bristol-Myers Squibb Company Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9765099B2 (en) * 2013-05-08 2017-09-19 Board Of Regents, The University Of Texas System STAT6 inhibitors
RU2019131017A (ru) * 2013-10-21 2019-11-25 Мерк Патент Гмбх Соединения гетероарила в качестве ингибиторов btk и их применение
JP6345786B2 (ja) 2013-12-05 2018-06-20 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
TW201609693A (zh) 2014-01-03 2016-03-16 必治妥美雅史谷比公司 雜芳基取代之菸鹼醯胺化合物
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2016022460A1 (en) 2014-08-03 2016-02-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Potent dual brd4-kinase inhibitors as cancer therapeutics
WO2016100308A1 (en) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-jun n-terminal kinase in skin
ES2877642T3 (es) 2014-12-16 2021-11-17 Signal Pharm Llc Formulaciones de 2-(terc-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CN107683139A (zh) 2015-05-29 2018-02-09 博尔托拉制药公司 用于治疗b细胞恶性肿瘤的赛度替尼
AR105113A1 (es) 2015-06-24 2017-09-06 Bristol Myers Squibb Co Compuestos de aminopiridina sustituida con heteroarilo
US10618903B2 (en) 2015-06-24 2020-04-14 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
UY36747A (es) 2015-06-24 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
EP3795553B1 (de) 2015-07-24 2024-05-15 Celgene Corporation Verfahren zur synthese von (1r,2r,5r)-5-amino-2-methylcyclohexanolhydrochlorid und nützliche zwischenprodukte darin
ES2913119T3 (es) 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
US10738016B2 (en) 2015-10-13 2020-08-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. BRD4-kinase inhibitors as cancer therapeutics
CN108367006B (zh) 2015-12-04 2021-12-31 博尔托拉制药公司 用于治疗血液癌症的赛度替尼
CN106222177B (zh) * 2016-08-13 2018-06-26 江苏集萃药康生物科技有限公司 一种靶向人STAT6的CRISPR-Cas9系统及其用于治疗过敏性疾病的应用
MY200228A (en) 2017-05-11 2023-12-15 Bristol Myers Squibb Co Thienopyridines and benzothiophenes useful as irak4 inhibitors
EP3737354A2 (de) 2018-01-09 2020-11-18 Dermavant Sciences GmbH Cerdulatinibhaltige pharmazeutische zusammensetzungen zur topischen anwendung auf der haut und verwendungen davon
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
WO2019213545A1 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
WO2021011724A1 (en) 2019-07-18 2021-01-21 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
WO2021011727A1 (en) 2019-07-18 2021-01-21 Bristol-Myers Squibb Company PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
CN114174279B (zh) 2019-08-06 2024-07-02 百时美施贵宝公司 可用作irak4抑制剂的双环杂环化合物
US12570659B2 (en) 2019-08-13 2026-03-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds useful as IRAK4 inhibitors
CN115335380B (zh) 2020-02-03 2024-08-02 百时美施贵宝公司 可用作irak4抑制剂的三环杂芳基化合物
US12391702B2 (en) 2020-02-03 2025-08-19 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
EP4257587A4 (de) * 2020-12-02 2025-01-08 Shenzhen Chipscreen Biosciences Co., Ltd. Hydroxamatverbindung, herstellungsverfahren dafür und anwendung davon
WO2022188735A1 (en) * 2021-03-08 2022-09-15 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as hpk1 inhibitors
CN116888100B (zh) * 2021-04-08 2025-12-23 杭州阿诺生物医药科技有限公司 一种高活性的hpk1激酶抑制剂
EP4401735A4 (de) * 2021-09-16 2025-07-16 Lomond Therapeutics Inc Verbindungen mit n-arylpyrimidin-2-amin-derivaten als therapeutische mittel
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
EP4538268A1 (de) * 2022-06-07 2025-04-16 Guangzhou Fermion Technology Co., Ltd. Pyridazin-3-carboxamidverbindung als tyk2-inhibitor
WO2025172431A1 (en) * 2024-02-14 2025-08-21 Almirall, S.A. Stat6 inhibitors and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839735D1 (de) * 1997-12-15 2008-08-28 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
BR9908004A (pt) 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
JP4529685B2 (ja) * 2002-06-28 2010-08-25 アステラス製薬株式会社 ジアミノピリミジンカルボキサミド誘導体

Also Published As

Publication number Publication date
EP1518855A1 (de) 2005-03-30
JP5104893B2 (ja) 2012-12-19
EP1518855B1 (de) 2011-10-26
WO2004002964A1 (ja) 2004-01-08
US7449456B2 (en) 2008-11-11
CN1665789A (zh) 2005-09-07
JP2010174027A (ja) 2010-08-12
US8012959B2 (en) 2011-09-06
US20050272753A1 (en) 2005-12-08
JPWO2004002964A1 (ja) 2005-10-27
ES2373226T3 (es) 2012-02-01
EP1518855A4 (de) 2007-03-14
MXPA04012855A (es) 2005-04-19
US20090281072A1 (en) 2009-11-12
AU2003244098A1 (en) 2004-01-19
US20110294749A1 (en) 2011-12-01
CA2490888A1 (en) 2004-01-08
CA2490888C (en) 2011-05-24
JP4529685B2 (ja) 2010-08-25

Similar Documents

Publication Publication Date Title
ATE530530T1 (de) Diaminopyrimidincarbonsäureamidderivat
WO2004037176A3 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
DK1864975T3 (da) Nikotinamid-derivater anvendelige som P38-inhibitorer
EP1511730B8 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE60332093D1 (de) Neues phenylalaninderivat
CA2388142A1 (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
WO2004043367A3 (en) Fused heterocyclic compounds and use thereof
WO2004002981A3 (en) Herbicidal thienylalkynes
NO20064577L (no) Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
MY140021A (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
BR0307071A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
WO2004043362A3 (en) Acyl guanidine compounds and use thereof
NO20044250L (no) Heterocykliske amid-derivativer for behandling av diabetes og andre sykdommer
MXPA05009282A (es) Derivados de anilina sustituidos.
WO2004041802A8 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
BR0314461A (pt) Processo para a preparação de derivado de 2-aminometilpiridina
DK1441726T3 (da) Derivater af phenoxy-N&#39; -4-(isothiazolidin-1,1-dioxid-2-yl)phenyl]-valerianesyreamid og andre forbindelser som inhibitorer af koagulationsfaktoren Xa til behandling af thromboemboliske lidelser og tumorer
WO2003063844A3 (en) Treatment of rheumatoid arthritis using imatinie
BRPI0314501C8 (pt) processo para a preparação de um derivado de 2-aminometilpiridina e processo para a preparação de um derivado de cloridrato de éster de glicina piridina
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties